[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA56286B1 - Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? - Google Patents

Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Info

Publication number
MA56286B1
MA56286B1 MA56286A MA56286A MA56286B1 MA 56286 B1 MA56286 B1 MA 56286B1 MA 56286 A MA56286 A MA 56286A MA 56286 A MA56286 A MA 56286A MA 56286 B1 MA56286 B1 MA 56286B1
Authority
MA
Morocco
Prior art keywords
immunocytokine
protein complex
complex based
heterodimeric protein
agent
Prior art date
Application number
MA56286A
Other languages
English (en)
Other versions
MA56286A1 (fr
Inventor
Stanislav Rudolfovich Evdokimov
Andrei Borisovich Ulitin
Sergei Andreevich Ageev
Ivan Vladimirovich Mitroshin
Alekseyvladimirovich Kononov
Aleksandr Andreevich Gordeev
Elena Vladimirovna Vinogradova
Aleksandra Pavlovna Shmakova
Dmitryvalentinovich Morozov
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of MA56286A1 publication Critical patent/MA56286A1/fr
Publication of MA56286B1 publication Critical patent/MA56286B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une immunocytokine comprenant un complexe hétéro-dimère protéinique à base de il-15/il-15ra, ainsi que son utilisation en qualité d'agent thérapeutique, notamment en qualité d'agent pour le traitement du cancer et d'une maladie auto-immune. La présente invention concerne également une immunocytokine comprenant un complexe hétéro-dimère protéinique à base de il-15/il-15ra et un anticorps immunomodulant, ainsi que son utilisation en qualité d'agent thérapeutique, notamment en qualité d'agent pour le traitement du cancer et d'une maladie auto-immune.
MA56286A 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r? MA56286B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2019129569A RU2753282C2 (ru) 2019-09-19 2019-09-19 ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
PCT/RU2020/050233 WO2021054867A1 (fr) 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15rα

Publications (2)

Publication Number Publication Date
MA56286A1 MA56286A1 (fr) 2023-05-31
MA56286B1 true MA56286B1 (fr) 2023-09-27

Family

ID=74873995

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56286A MA56286B1 (fr) 2019-09-19 2020-09-20 Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?

Country Status (18)

Country Link
US (1) US20230011234A1 (fr)
EP (1) EP4032539A4 (fr)
JP (1) JP2022549276A (fr)
KR (1) KR20220145323A (fr)
CN (1) CN115297885A (fr)
AR (1) AR120011A1 (fr)
AU (1) AU2020351560A1 (fr)
BR (1) BR112022005173A2 (fr)
CA (1) CA3151780A1 (fr)
CO (1) CO2022003156A2 (fr)
JO (1) JOP20220071A1 (fr)
MA (1) MA56286B1 (fr)
MX (1) MX2022003306A (fr)
PE (1) PE20220603A1 (fr)
RU (1) RU2753282C2 (fr)
TW (1) TW202124420A (fr)
UY (1) UY38889A (fr)
WO (1) WO2021054867A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3856764A4 (fr) 2018-09-27 2022-11-02 Xilio Development, Inc. Polypeptides de cytokine masqués
WO2023133595A2 (fr) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Méthodes de dosage et d'administration ex vivo de particules lipidiques ou de vecteurs viraux ainsi que systèmes et utilisations associés
CN115141283A (zh) * 2022-03-10 2022-10-04 厦门柏慈生物科技有限公司 一种融合蛋白、制备方法及其应用
WO2023193015A1 (fr) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Polythérapies d'agoniste de récepteur de cytokine et de vecteur viral
CN116854821A (zh) * 2022-08-15 2023-10-10 海徕科(北京)生物技术有限公司 IL-15突变体-Fc/IL-15Rα亚基-Fc异源二聚体及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
WO1986005807A1 (fr) 1985-04-01 1986-10-09 Celltech Limited Lignee cellulaire de myelomes transformee et procede d'expression d'un gene codant un polypeptide eucaryotque employant cette lignee
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP1777294A1 (fr) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) Le domaine sushi de IL-15Ralpha comme enhancer sélectif et efficace de l'action de f IL-15 grâce à IL-15Rbeta/gamma, et l' hyperagoniste (IL15Ralpha sushi -IL15) comme protéine fusion
CA2811734C (fr) * 2010-09-21 2021-11-23 Altor Bioscience Corporation Molecules de fusion multimeres solubles a base d'il-15, leurs procedes de preparation et d'utilisation
EP2537933A1 (fr) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) Immunocytokines basées sur le domaine IL-15 et IL-15Ralpha sushi
EP3444271B1 (fr) 2013-08-08 2021-10-06 Cytune Pharma Modulokines basées sur l'il-15 et le domaine sushi de il-15r-alpha
WO2015103928A1 (fr) * 2014-01-08 2015-07-16 上海恒瑞医药有限公司 Protéine dimérique hétérogène il-15 et ses utilisations
CA2953816C (fr) * 2014-06-30 2022-03-15 Altor Bioscience Corporation Molecules a base de il-15 et leurs procedes d'utilisation
KR102609197B1 (ko) 2014-12-19 2023-12-05 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 인터류킨 15 단백질 복합체 및 그의 용도
RU2656181C1 (ru) 2016-07-13 2018-05-31 Закрытое Акционерное Общество "Биокад" Анти-pd-1-антитела, способ их получения и способ применения
KR102649972B1 (ko) * 2016-10-14 2024-03-22 젠코어 인코포레이티드 IL15/IL15Rα 이종이량체 Fc-융합 단백질
BR112019007920A2 (pt) * 2016-10-21 2019-10-08 Altor Bioscience Corp moléculas multiméricas à base de il-15
US11129883B2 (en) * 2017-03-06 2021-09-28 Altor BioScience, LLC. IL-15-based fusions to IL-12 and IL-18
RU2665790C1 (ru) 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
JP2020530280A (ja) * 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用

Also Published As

Publication number Publication date
PE20220603A1 (es) 2022-04-25
EP4032539A1 (fr) 2022-07-27
AU2020351560A1 (en) 2022-11-24
JOP20220071A1 (ar) 2023-01-30
KR20220145323A (ko) 2022-10-28
WO2021054867A1 (fr) 2021-03-25
AR120011A1 (es) 2022-01-26
CA3151780A1 (fr) 2021-03-25
MA56286A1 (fr) 2023-05-31
CN115297885A (zh) 2022-11-04
RU2019129569A3 (fr) 2021-03-19
US20230011234A1 (en) 2023-01-12
MX2022003306A (es) 2022-04-26
UY38889A (es) 2021-04-30
RU2019129569A (ru) 2021-03-19
JP2022549276A (ja) 2022-11-24
BR112022005173A2 (pt) 2022-08-16
TW202124420A (zh) 2021-07-01
RU2753282C2 (ru) 2021-08-12
EP4032539A4 (fr) 2023-09-13
CO2022003156A2 (es) 2022-04-19

Similar Documents

Publication Publication Date Title
MA56286B1 (fr) Immunocytokine comprenant un complexe protéinique hétéro-dimère à base de il-15 et il-15r?
Hos et al. Identification of a neo-epitope dominating endogenous CD8 T cell responses to MC-38 colorectal cancer
Dufour et al. C-terminal truncation of IFN-γ inhibits proinflammatory macrophage responses and is deficient in autoimmune disease
Puren et al. Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1β are differentially regulated in human blood mononuclear cells and mouse spleen cells
MA31899B1 (fr) Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
EP1461081A4 (fr) Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon
MA28149A1 (fr) Compositions de vaccin comprenant une interleukine 18 et un systeme adjuvant de type saponine
HUP0401591A2 (hu) Új receptor-nukleinsavak és- polipeptidek
ATE364618T1 (de) Antikörper gegen das muc18-antigen
NZ595262A (en) Use of il-23 and il-27 antagonists to treat autoimmune ocular inflammatory disease
DK1272515T3 (da) Immunregulator
BRPI0409910A (pt) métodos para o tratamento de doenças relacionadas com interleucina-6
MA44334A (fr) Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
HUP0300423A2 (hu) Emberi interleukin-18-at megkötni képes antitestek és ezek előállítására és alkalmazására szolgáló eljárások
MA30353B1 (fr) Anticorps se liant à la protéine tyrosine phosphatase bêta humaine (hptpbêta) et utilisations correspondantes.
MA32892B1 (fr) Anticorps anti-cmet
BR0113213A (pt) Método para diagnosticar uma doença auto-imune, anticorpo, composição de diagnóstico, e, uso do anticorpo
DK1082131T3 (da) Immunoregulator
EE03697B1 (et) Interleukiin-1 retseptori antagonisti intratsellulaarne isovorm
DE59809283D1 (de) Inhibitoren für den urokinaserezeptor
ATE383878T1 (de) Licht emittierende fusionsproteine sowie diagnose-und therapieverfahren dafür
NO20065473L (no) IL-6RL/IL-6-kimaerer for terapi av kjemoterapeutisk indusert perifer nevropati.
CO5690618A2 (es) Agente terapeutico para el mesotelioma
MA32080B1 (fr) Vaccin comprenant un extrait de protéine ribosomale (rpe) et facultativement un adjuvant promouvant la réponse th1
FR2832155B1 (fr) Anticorps stimulant la production d'il-1ra